Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307656 · ClinicalTrials.gov registry record · Phase 1
Taste Properties of Atazanavir and Cobicistat
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02307656 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 6 participants.
The verdict
NCT02307656, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objective is to assess the taste properties of atazanavir (ATV) and cobicistat (COBI) alone and in combination as well as oral test formulations containing both ATV and COBI.
Interventions
- DRUG Cobicistat
- DRUG Atazanavir
- DRUG Active Pharmaceutical Ingredient
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12-12 |
| Est. Completion | 2021-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02307656
The ClinicalTrials.gov registry entry for NCT02307656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cobicistat is the first listed.
NCT02307656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02307656 about?
NCT02307656 is a clinical study titled "Taste Properties of Atazanavir and Cobicistat". The primary objective is to assess the taste properties of atazanavir (ATV) and cobicistat (COBI) alone and in combination as well as oral test formulations containing both ATV and COBI.
What is the current status of trial NCT02307656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-12-12. Estimated completion is 2021-09-09.
What interventions are being tested in trial NCT02307656?
The interventions under investigation include: Cobicistat (DRUG), Atazanavir (DRUG), Active Pharmaceutical Ingredient (DRUG).
Who is sponsoring clinical trial NCT02307656?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.